151 related articles for article (PubMed ID: 17870150)
1. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Havrilesky LJ; Secord AA; Kulasingam S; Myers E
Gynecol Oncol; 2007 Nov; 107(2):211-8. PubMed ID: 17870150
[TBL] [Abstract][Full Text] [Related]
2. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
[TBL] [Abstract][Full Text] [Related]
4. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
Cohn DE; Barnett JC; Wenzel L; Monk BJ; Burger RA; Straughn JM; Myers ER; Havrilesky LJ
Gynecol Oncol; 2015 Feb; 136(2):293-9. PubMed ID: 25449568
[TBL] [Abstract][Full Text] [Related]
5. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Giuliani J; Bonetti A
Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
7. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
8. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
Dalton HJ; Yu X; Hu L; Kapp DS; Benjamin I; Monk BJ; Chan JK
Gynecol Oncol; 2012 Feb; 124(2):199-204. PubMed ID: 22055763
[TBL] [Abstract][Full Text] [Related]
9. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
[TBL] [Abstract][Full Text] [Related]
10. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Pfisterer J; Plante M; Vergote I; du Bois A; Hirte H; Lacave AJ; Wagner U; Stähle A; Stuart G; Kimmig R; Olbricht S; Le T; Emerich J; Kuhn W; Bentley J; Jackisch C; Lück HJ; Rochon J; Zimmermann AH; Eisenhauer E; ; ;
J Clin Oncol; 2006 Oct; 24(29):4699-707. PubMed ID: 16966687
[TBL] [Abstract][Full Text] [Related]
14. Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J; Ledermann JA
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
Pfisterer J; Vergote I; Du Bois A; Eisenhauer E; ; ;
Int J Gynecol Cancer; 2005; 15 Suppl 1():36-41. PubMed ID: 15839957
[TBL] [Abstract][Full Text] [Related]
16. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
Rocconi RP; Case AS; Straughn JM; Estes JM; Partridge EE
Cancer; 2006 Aug; 107(3):536-43. PubMed ID: 16804928
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
[TBL] [Abstract][Full Text] [Related]
18. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
[TBL] [Abstract][Full Text] [Related]
19. NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
Pinilla-Dominguez P; Richardson J; Robertson J; Adam J
Lancet Oncol; 2013 Jul; 14(8):691-2. PubMed ID: 23706986
[No Abstract] [Full Text] [Related]
20. Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Chisaki Y; Nakamura N; Yano Y
Biol Pharm Bull; 2017; 40(1):73-81. PubMed ID: 28049952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
